Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Stadler, R.
Gastrointestinal stromal tumour-Literature review and retrospective analysis of 66 upper gastrointestinal GISTs
Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2017. pp. 60
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Bacher Heinz
- Thalhammer Michael
- Altmetrics:
- Abstract:
- Background/Aims Main objective of the literature review was to provide an overview on gastrointestinal stromal tumours, the most common mesenchymal tumour of the gastrointestinal tract. The results of the conducted retrospective analysis should show if the analysed cases and related data of upper GItract GISTs are comparable to those found in literature. We hope to draw conclusions with regard to follow-up care. Methods We retrospectively analysed 66 cases of upper GI-tract GISTs who were treated at the clinical department of general surgery, medical university of Graz. Inclusion criteria were operable GIST originating from the oesophagus, stomach or duodenum. Results Of the 66 analysed patients, 38 (57,6%) were male and 28 (42,4%) female, with a median age of 63 years (range 11 to 74) at the time of surgery. 3 patients were diagnosed with GIST related syndromes. Resection margin was R0 in 57 cases (86,5%), R1 in 2 cases (3%), and R2 in 5 cases (7,5%), respectively. Median tumour diameter was 4,1cm. Mitotic count was <5 in 46 cases (69,7%). For risk assessment the AFIP classification was used. 9 patients (13,6%) were administered adjuvant imatinib. 3 patients (4,5%) received neoadjuvant imatinib. 5 patients (7,5%) received imatinib after surgery because of disease progression. 5 patients (7,6%) had metastasis at the time of diagnosis, but where deemed resectable by the local tumour board Two other patients with metastatic disease received imatinib after surgery. Patients were followed for a median of 61 months (inter-quartile range 30 to 101 months). A total of 10 patients (15,2%) showed disease progression after surgery. The median time to recurrence was 38,5 months (2 to 69 months). The 5 year recurrence free survival rate was 86,4%. A total of 13 patients (19,7%) died during follow-up. Discussion Treatment and prognosis of GISTs has greatly improved in the past decade. Still, there is need for more research in some fields. The results series correlated well with information found literature. With regard to follow-up, we suggest that patients with no, very low, and low risk GISTs should not be followed-up regularly. Reliable conclusions are limited because of the retrospective design and the case number of our study.